475 related articles for article (PubMed ID: 23370522)
1. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
Tsuji D
Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
[TBL] [Abstract][Full Text] [Related]
2. Metabolic correction in microglia derived from Sandhoff disease model mice.
Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Itoh K
J Neurochem; 2005 Sep; 94(6):1631-8. PubMed ID: 16092933
[TBL] [Abstract][Full Text] [Related]
3. The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment.
Toro C; Zainab M; Tifft CJ
Neurosci Lett; 2021 Nov; 764():136195. PubMed ID: 34450229
[No Abstract] [Full Text] [Related]
4. Novel bicistronic lentiviral vectors correct β-Hexosaminidase deficiency in neural and hematopoietic stem cells and progeny: implications for in vivo and ex vivo gene therapy of GM2 gangliosidosis.
Ornaghi F; Sala D; Tedeschi F; Maffia MC; Bazzucchi M; Morena F; Valsecchi M; Aureli M; Martino S; Gritti A
Neurobiol Dis; 2020 Feb; 134():104667. PubMed ID: 31682993
[TBL] [Abstract][Full Text] [Related]
5. Improvement of motor and behavioral activity in Sandhoff mice transplanted with human CD34+ cells transduced with a HexA/HexB expressing lentiviral vector.
Beegle J; Hendrix K; Maciel H; Nolta JA; Anderson JS
J Gene Med; 2020 Sep; 22(9):e3205. PubMed ID: 32335981
[TBL] [Abstract][Full Text] [Related]
6. Specific induction of macrophage inflammatory protein 1-alpha in glial cells of Sandhoff disease model mice associated with accumulation of N-acetylhexosaminyl glycoconjugates.
Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Kuwahara J; Yamanaka S; Itoh K
J Neurochem; 2005 Mar; 92(6):1497-507. PubMed ID: 15748167
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
[TBL] [Abstract][Full Text] [Related]
8. Western blotting analysis of the beta-hexosaminidase alpha- and beta-subunits in cultured fibroblasts from cases of various forms of GM2 gangliosidosis.
Utsumi K; Tsuji A; Kase R; Tanaka A; Tanaka T; Uyama E; Ozawa T; Sakuraba H; Komaba Y; Kawabe M; Iino Y; Katayama Y
Acta Neurol Scand; 2002 Jun; 105(6):427-30. PubMed ID: 12027830
[TBL] [Abstract][Full Text] [Related]
9. Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis.
Tsuji D; Akeboshi H; Matsuoka K; Yasuoka H; Miyasaki E; Kasahara Y; Kawashima I; Chiba Y; Jigami Y; Taki T; Sakuraba H; Itoh K
Ann Neurol; 2011 Apr; 69(4):691-701. PubMed ID: 21520232
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic evaluation of GM2 gangliosidoses by ELISA using anti-GM2 ganglioside antibodies.
Tsuji D; Higashine Y; Matsuoka K; Sakuraba H; Itoh K
Clin Chim Acta; 2007 Mar; 378(1-2):38-41. PubMed ID: 17196574
[TBL] [Abstract][Full Text] [Related]
11. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases.
Ou L; Przybilla MJ; Tăbăran AF; Overn P; O'Sullivan MG; Jiang X; Sidhu R; Kell PJ; Ory DS; Whitley CB
Gene Ther; 2020 May; 27(5):226-236. PubMed ID: 31896760
[TBL] [Abstract][Full Text] [Related]
12. GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients.
Gort L; de Olano N; Macías-Vidal J; Coll MA;
Gene; 2012 Sep; 506(1):25-30. PubMed ID: 22789865
[TBL] [Abstract][Full Text] [Related]
13. Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice.
Itakura T; Kuroki A; Ishibashi Y; Tsuji D; Kawashita E; Higashine Y; Sakuraba H; Yamanaka S; Itoh K
Biol Pharm Bull; 2006 Aug; 29(8):1564-9. PubMed ID: 16880605
[TBL] [Abstract][Full Text] [Related]
14. Brain endothelial specific gene therapy improves experimental Sandhoff disease.
Dogbevia G; Grasshoff H; Othman A; Penno A; Schwaninger M
J Cereb Blood Flow Metab; 2020 Jun; 40(6):1338-1350. PubMed ID: 31357902
[TBL] [Abstract][Full Text] [Related]
15. Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta.
Akeboshi H; Chiba Y; Kasahara Y; Takashiba M; Takaoka Y; Ohsawa M; Tajima Y; Kawashima I; Tsuji D; Itoh K; Sakuraba H; Jigami Y
Appl Environ Microbiol; 2007 Aug; 73(15):4805-12. PubMed ID: 17557860
[TBL] [Abstract][Full Text] [Related]
16. Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice.
Lahey HG; Webber CJ; Golebiowski D; Izzo CM; Horn E; Taghian T; Rodriguez P; Batista AR; Ellis LE; Hwang M; Martin DR; Gray-Edwards H; Sena-Esteves M
Mol Ther; 2020 Oct; 28(10):2150-2160. PubMed ID: 32592687
[TBL] [Abstract][Full Text] [Related]
17. Protease-resistant modified human β-hexosaminidase B ameliorates symptoms in GM2 gangliosidosis model.
Kitakaze K; Mizutani Y; Sugiyama E; Tasaki C; Tsuji D; Maita N; Hirokawa T; Asanuma D; Kamiya M; Sato K; Setou M; Urano Y; Togawa T; Otaka A; Sakuraba H; Itoh K
J Clin Invest; 2016 May; 126(5):1691-703. PubMed ID: 27018595
[TBL] [Abstract][Full Text] [Related]
18. Genetics and Therapies for GM2 Gangliosidosis.
Cachon-Gonzalez MB; Zaccariotto E; Cox TM
Curr Gene Ther; 2018; 18(2):68-89. PubMed ID: 29618308
[TBL] [Abstract][Full Text] [Related]
19. Introduction of an N-glycan sequon into HEXA enhances human beta-hexosaminidase cellular uptake in a model of Sandhoff disease.
Matsuoka K; Tsuji D; Aikawa S; Matsuzawa F; Sakuraba H; Itoh K
Mol Ther; 2010 Aug; 18(8):1519-26. PubMed ID: 20571546
[TBL] [Abstract][Full Text] [Related]
20. Combined replacement effects of human modified β-hexosaminidase B and GM2 activator protein on GM2 gangliosidoses fibroblasts.
Kitakaze K; Tasaki C; Tajima Y; Hirokawa T; Tsuji D; Sakuraba H; Itoh K
Biochem Biophys Rep; 2016 Sep; 7():157-163. PubMed ID: 28955902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]